Nivalis Therapeutics Inc (NVLS) Raised to “Purchase” at Vetr Inc.

Nivalis Therapeutics Inc (NVLS) Raised to “Purchase” at Vetr Inc.

Nivalis Therapeutics Inc (NASDAQ:NVLS) was upgraded by equities researchers at Vetr from a “hold” rating to a “buy” rating in a report released on Monday. The firm currently has a $2.50 target price on the stock. Vetr‘s price objective indicates a potential downside of 14.38% from the company’s previous close.

NVLS has been the subject of a number of other reports. Robert W. Baird lowered shares of Nivalis Therapeutics from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $29.00 to $3.00 in a research note on Tuesday, November 29th. Raymond James Financial, Inc. lowered shares of Nivalis Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 29th. Zacks Investment Research raised shares of Nivalis Therapeutics from a “sell” rating to a “buy” rating and set a $8.50 price objective for the company in a research note on Thursday, October 20th. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective (down from $30.00) on shares of Nivalis Therapeutics in a research note on Tuesday, November 29th. Finally, Cowen and Company lowered shares of Nivalis Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 29th. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the stock. Nivalis Therapeutics has a consensus rating of “Hold” and a consensus price target of $8.07.

Shares of Nivalis Therapeutics (NASDAQ:NVLS) traded up 3.18% during mid-day trading on Monday, hitting $2.92. 143,466 shares of the stock were exchanged. The firm’s market cap is $45.72 million. Nivalis Therapeutics has a 52-week low of $2.00 and a 52-week high of $9.35. The stock has a 50-day moving average price of $2.74 and a 200 day moving average price of $4.22.

Nivalis Therapeutics (NASDAQ:NVLS) last issued its earnings results on Monday, February 13th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.05. During the same quarter in the previous year, the business earned ($0.42) EPS. On average, equities research analysts expect that Nivalis Therapeutics will post ($1.16) earnings per share for the current year.

A number of hedge funds have recently added to or reduced their stakes in NVLS. Sphera Funds Management LTD. acquired a new stake in Nivalis Therapeutics during the third quarter worth $1,664,000. Endurant Capital Management LP raised its stake in Nivalis Therapeutics by 29.8% in the third quarter. Endurant Capital Management LP now owns 85,412 shares of the company’s stock worth $694,000 after buying an additional 19,629 shares during the period. Spark Investment Management LLC acquired a new stake in Nivalis Therapeutics during the third quarter worth $145,000. Finally, Perceptive Advisors LLC acquired a new stake in Nivalis Therapeutics during the fourth quarter worth $274,000. 75.85% of the stock is owned by institutional investors.

About Nivalis Therapeutics

Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.

To view Vetr’s full report, visit Vetr’s official website.

Related posts

Leave a Comment